- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 211513-37-0] Dalcetrapib
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-14950 |
| Brand: | MCE |
| CAS: | 211513-37-0 |
Overview
| MDL | MFCD06407886 |
|---|---|
| Molecular Weight | 389.59 |
| Molecular Formula | C23H35NO2S |
| SMILES | CC(C)C(SC1=C(NC(C2(CC(CC)CC)CCCCC2)=O)C=CC=C1)=O |
Summary
In Vitro
In Vivo
Dalcetrapib (JTT-705) (30 or 100 mg/kg; p.o.; once a day for 3 days) increases plasma HDL cholesterol in rabbits
[2]
.
Dalcetrapib (100 mg/kg; i.g.; twice daily for 7 days) significantly increases fecal elimination of neutral sterols, bile acids, and plasma HDL-cholesterol
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Male JW rabbits [2] |
| Dosage: | 30 or 100 mg/kg |
| Administration: | Oral administration, once a day for 3 days |
| Result: | Increased plasma HDL cholesterol by 27% and 54% at 30 mg/kg and 100 mg/kg, respectively. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01476267 | Hoffmann-La Roche |
Healthy Volunteer
|
October 2011 | Phase 1 |
| NCT01323153 | Hoffmann-La Roche |
Coronary Heart Disease
|
March 2011 | Phase 3 |
| NCT00697203 | Hoffmann-La Roche |
Dyslipidemia
|
July 2005 | Phase 2 |
| NCT01059682 | Hoffmann-La Roche |
Cardiovascular Disease
|
January 2010 | Phase 3 |
| NCT01363999 | Hoffmann-La Roche |
Healthy Volunteer
|
June 2011 | Phase 1 |
| NCT00658515 | Hoffmann-La Roche |
Coronary Heart Disease
|
April 2008 | Phase 3 |
| NCT00689442 | Akros Pharma Inc. |
Dyslipidemia
|
January 2004 | Phase 2 |
| NCT00688558 | Akros Pharma Inc. |
Dyslipidemia
|
February 2004 | Phase 2 |
| NCT00655538 | Hoffmann-La Roche |
Coronary Heart Disease
|
February 2008 | Phase 2 |
| NCT04676867 | DalCor Pharmaceuticals|The Montreal Health Innovations Coordinating Center (MHICC)|Covance |
Covid19
|
January 11, 2021 | Phase 2 |
| NCT01516541 | Hoffmann-La Roche |
Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
|
January 2012 | Phase 3 |
| NCT00686010 | Japan Tobacco Inc. |
Type II Hyperlipidaemia
|
May 2000 | Phase 2 |
| NCT00353522 | Hoffmann-La Roche |
Coronary Heart Disease
|
July 2006 | Phase 2 |
| NCT00688896 | Akros Pharma Inc. |
Type II Hyperlipidemia
|
June 2002 | Phase 2 |
| NCT00655473 | Hoffmann-La Roche |
Coronary Heart Disease
|
March 2008 | Phase 2 |
| NCT02525939 | DalCor Pharmaceuticals|The Montreal Health Innovations Coordinating Center (MHICC)|Medpace, Inc.|Roche Molecular Systems, Inc |
Acute Coronary Syndrome
|
April 2016 | Phase 3 |
| NCT00400439 | Hoffmann-La Roche |
Coronary Heart Disease
|
January 2007 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 50 mg/mL ( 128.34 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.5668 mL | 12.8340 mL | 25.6680 mL |
| 5 mM | 0.5134 mL | 2.5668 mL | 5.1336 mL |
| 10 mM | 0.2567 mL | 1.2834 mL | 2.5668 mL |
References
- [1] Niesor EJ, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport. J Lipid Res. 2010, 51(12), 3443-3454.
- [2] Shinkai H, et al. J Med Chem. bis(2-(Acylamino)phenyl) disulfides, 2-(acylamino)benzenethiols, and S-(2-(acylamino)phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein. 2000, 43(19), 3566-3572.
- [3] Huang Z, et al. Dual effects on HDL metabolism by cholesteryl ester transfer protein inhibition in HepG2 cells. Am J Physiol Endocrinol Metab. 2003, 284(6), E1210-E1219.
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.